Acquiring Company
Ikena Oncology
Acquired Company
Pionyr Immunotherapeutics
BostonBiotechnologyHealth CareMedicalTherapeuticsBiotechnologyHealth CareDescription
Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. (Pionyr), a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena’s acquisition of Pionyr in an all-stock transaction. Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible preferred stock priced at $7.15 per share.
Quick answer
Ikena Oncology is acquiring Pionyr Immunotherapeutics, announced August 7, 2023. Ikena Oncology is based in Boston, Massachusetts, United States.
- How much did Ikena Oncology pay for Pionyr Immunotherapeutics?
- The deal value was not disclosed.
- What does Ikena Oncology do?
- Ikena OncologyTM is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network.
- Where are Ikena Oncology and Pionyr Immunotherapeutics based?
- Ikena Oncology is based in Boston, Massachusetts, United States.
- Who are the decision-makers at Ikena Oncology?
- Fundz holds 1 contact at Ikena Oncology. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Scilex Holding Company Announces The Consummation Of The Previously Announced Purchase Of All Of The Scilex Common Shares, Preferred Shares And Warrants Owned By Sorrento Therapeutics, Inc. (September 21, 2023)
- Caldera Medical Acquires Atlantic Therapeutics To Expand Portfolio In Women’S Health (September 6, 2023)
- Labgenomics Usa Llc Acquires Qdx Pathology In A Strategic Move To Expand Its Diagnostic Lab Services And Ivd Diagnostic Products Business Into The Us Market (September 5, 2023)
- Rqm+™ Acquires Germany Based Cro Kottmann (August 28, 2023)
- Theken Companies Acquires Visionair Solutions (August 22, 2023)
- Lilly Completes Acquisition Of Dice Therapeutics (August 9, 2023)
Who to call at Ikena Oncology, and when
When Ikena Oncology changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Ikena Oncology raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ikena Oncology, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ikena Oncology. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ikena Oncology makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Pionyr Immunotherapeutics?
Pionyr Immunotherapeutics was acquired by Ikena Oncology, based in Boston. The deal was reported on August 7, 2023. Ikena OncologyTM is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Ikena Oncology is privately held and operates in Biotechnology.
When did Ikena Oncology acquire Pionyr Immunotherapeutics?
Ikena Oncology's acquisition of Pionyr Immunotherapeutics was reported on August 7, 2023. Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Pionyr Immunotherapeutics do?
Pionyr’s programs exploit novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics after checkpoint inhibitors. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.